Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
brexpiprazole | ANDA | 2025-06-27 |
rexulti | New Drug Application | 2025-06-18 |
Expiration | Code | ||
---|---|---|---|
BREXPIPRAZOLE, REXULTI, OTSUKA | |||
2026-05-10 | I-913 | ||
2024-12-27 | NPP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | 10 | 3 | 16 | 1 | 1 | 30 |
Depression | D003863 | — | F33.9 | 1 | 4 | 15 | 3 | 1 | 23 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 4 | 15 | 3 | 1 | 23 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 4 | 15 | 2 | — | 21 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | 3 | 1 | — | 5 |
Psychotic disorders | D011618 | — | F20.81 | 1 | — | — | 1 | 1 | 3 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | 7 | — | 1 | 9 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 6 | — | 2 | 8 |
Dementia | D003704 | EFO_0003862 | F03 | — | 1 | 5 | — | 2 | 7 |
Psychomotor agitation | D011595 | — | — | — | 1 | 6 | — | 1 | 7 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 2 | 3 | — | — | 6 |
Traumatic stress disorders | D040921 | — | — | 1 | 2 | 3 | — | — | 6 |
Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | 5 | — | — | 5 |
Nervous system diseases | D009422 | — | G00-G99 | 1 | — | 2 | — | 1 | 4 |
Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | — | 2 | — | — | 3 |
Borderline personality disorder | D001883 | — | F60.3 | — | 3 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperkinesis | D006948 | — | — | — | 1 | — | — | — | 1 |
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Central nervous system diseases | D002493 | — | G96.9 | 1 | — | — | — | — | 1 |
Conduct disorder | D019955 | EFO_0004216 | F91 | 1 | — | — | — | — | 1 |
Attention deficit and disruptive behavior disorders | D019958 | — | F91.3 | 1 | — | — | — | — | 1 |
Oppositional defiant disorder | D000096865 | — | — | 1 | — | — | — | — | 1 |
Problem behavior | D000066553 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Aggression | D000374 | EFO_0003015 | — | — | — | — | — | 1 | 1 |
Drug common name | Brexpiprazole |
INN | brexpiprazole |
Description | Brexpiprazole is a N-arylpiperazine. |
Classification | Small molecule |
Drug class | antiulcer agents (benzimidazole derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1 |
PDB | — |
CAS-ID | 913611-97-9 |
RxCUI | — |
ChEMBL ID | CHEMBL2105760 |
ChEBI ID | — |
PubChem CID | 11978813 |
DrugBank | DB09128 |
UNII ID | 2J3YBM1K8C (ChemIDplus, GSRS) |